Aethlon Medical, Inc. (NASDAQ:AEMD) Sees Large Drop in Short Interest

Aethlon Medical, Inc. (NASDAQ:AEMD) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 479,400 shares, a decrease of 52.0% from the February 13th total of 998,100 shares. Currently, 3.4% of the shares of the company are short sold. Based on an average daily volume of 3,170,000 shares, the days-to-cover ratio is currently 0.2 days.

Aethlon Medical Price Performance

Aethlon Medical stock opened at $0.37 on Friday. The business has a 50 day simple moving average of $0.62 and a 200-day simple moving average of $0.50. Aethlon Medical has a 12 month low of $0.24 and a 12 month high of $1.85. The stock has a market capitalization of $5.40 million, a PE ratio of -0.24 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last released its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.09. As a group, equities research analysts anticipate that Aethlon Medical will post -0.73 EPS for the current year.

Institutional Investors Weigh In On Aethlon Medical

Institutional investors have recently added to or reduced their stakes in the business. Boothbay Fund Management LLC acquired a new stake in shares of Aethlon Medical in the 4th quarter valued at approximately $186,000. Sassicaia Capital Advisers LLC purchased a new position in Aethlon Medical in the fourth quarter worth $31,000. Renaissance Technologies LLC acquired a new stake in Aethlon Medical in the fourth quarter valued at $25,000. Virtu Financial LLC purchased a new stake in shares of Aethlon Medical during the 4th quarter worth $81,000. Finally, Allegiance Financial Group Advisory Services LLC acquired a new position in shares of Aethlon Medical during the 4th quarter worth $26,000. Hedge funds and other institutional investors own 1.99% of the company’s stock.

Analyst Ratings Changes

AEMD has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Aethlon Medical in a research report on Monday, March 10th. StockNews.com assumed coverage on Aethlon Medical in a research report on Wednesday. They issued a “sell” rating on the stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.